<DOC>
	<DOCNO>NCT01359228</DOCNO>
	<brief_summary>The purpose study determine effect rifaximin skin symptom patient rosacea double-blinded , placebo-controlled , crossover study .</brief_summary>
	<brief_title>Rifaximin Treatment Papulopustular Rosacea</brief_title>
	<detailed_description>100 patient randomize two group . Group A receive one rifaximin 550 mg tablet three time day ( 1650 mg/day ) 14 day , 4-week washout period , receive one placebo tablet three time day 14 day . Group B receive placebo first , rifaximin dosage schedule Group A . Assessments perform application 4 week last dosage , rifaximin placebo .</detailed_description>
	<mesh_term>Rosacea</mesh_term>
	<mesh_term>Rifaximin</mesh_term>
	<mesh_term>Rifamycins</mesh_term>
	<criteria>Males female &gt; 18 year age rosacea define : 340 papules/pustules &lt; 2 nodule , A score 24 Investigator Global Assessment Untreated pancreatic insufficiency Crohn 's disease Ulcerative colitis Active celiac disease clinical history End stage renal failure Less 18 year old Pregnancy positive pregnancy test Rosacea subtype 1 ( papule ) Topical oral antibiotic within 4 week Acne treatment within 4 week prior randomization Systemic retinoids within 90 day Topical systemic corticosteroid 4 week prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Rosacea</keyword>
</DOC>